EUROASPIRE III: a survey on the lifestyle,risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries

Abstract

Aim

The aim of the European Action on Secondary and Primary Prevention by Intervention to Reduce Events III (EUROASPIRE III) survey was to determine whether the Joint European Societies' guidelines on cardiovascular prevention are being followed in everyday clinical practice and to describe the lifestyle, risk factor and therapeutic management in patients with coronary heart disease (CHD) in Europe.

Methods

The EUROASPIRE III survey was carried out in 2006-2007 in 76 centres from selected geographical areas in 22 countries in Europe. Consecutive patients, with a clinical diagnosis of CHD, were identified retrospectively and then followed up, interviewed and examined at least 6 months after their coronary event.

Results

Thirteen thousand nine hundred and thirty-five medical records (27% women) were reviewed and 8966 patients were interviewed. At interview, 17% of patients smoked cigarettes, 35% were obese and 53% centrally obese, 56% had a blood pressure ≥140/90 mmHg (≥130/80 in people with diabetes mellitus), 51% had a serum total cholesterol ≥4.5 mmol/l and 25% reported a history of diabetes of whom 10% had a fasting plasma glucose less than 6.1 mmol/l and 35% a glycated haemoglobin A1c less than 6.5%. The use of cardioprotective medication was: antiplatelets 91%; β-blockers 80%; angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers 71%; calcium channel blockers 25% and statins 78%.

Conclusion

The EUROASPIRE III survey shows that large proportions of coronary patients do not achieve the lifestyle, risk factor and therapeutic targets for cardiovascular disease prevention. Wide variations in risk factor prevalences and the use of cardioprotective drug therapies exist between countries. There is still considerable potential throughout Europe to raise standards of preventive care in order to reduce the risk of recurrent disease and death in patients with CHD. Eur J Cardiovasc Prev Rehabil 16:121-137 © 2009 The European Society of Cardiology

Keywords

cardiovascular prevention EUROASPIRE guidelines

Get full access to this article

View all access options for this article.

References

Graham

Atar

Borch-Johnsen

Boysen

Burell

Cifkova

European Guidelines on Cardiovascular Disease Prevention in Clinical Practice: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)

Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl 2): S1–S113. Executive summary: Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl 2): E1–E40; Eur Heart J 2007; 28:2375–2414.

2 Allender

Scharbotough

Peto

Rayner

Leal

Luengo-Fernández

Gray

. European cardiovascular disease statistics: 2008 edition. London: British Heart Foundation; 2008.

3 Lopez

Mathers

Ezzati

Jamison

Murray

. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367:1747–1757.

4 Pyörälä

De Backer

Graham

Poole-Wilson

Wood

. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerotic Society and European Society of Hypertension. Eur Heart J 1994; 15:1300–1331.

5 Wood

De Backer

Faergeman

Graham

Mancia

Pyörälä

. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19:1434–1503.

De Backer

Ambrosioni

Borch-Johnsen

Brotons

Cifkova

Dallongeville

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts)

Eur J Cardiovasc Prev Rehabil 2003; 10 (Suppl 1):S1–S78.

7 EUROASPIRE Study Group. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997; 18:1569–1582.

8 EUROASPIRE Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Euro Heart Survey Programme. Eur Heart J 2001; 22:554–572.

9 EUROASPIRE Study Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001; 357:995–1001.

10.

10 Kotseva K, Wood D, De Backer G, De Bacquer D, Wilson K, Pyörälä K, Keil U, for the EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373:929–940.

11.

11 Wilson

Gibson

Willan

Cook

. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. Arch Intern Med 2000; 160:939–944.

12.

12 Bucher

Hengstler

Schindler

Meier

. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002; 112:298–304.

13.

Taylor

Brown

Ebrahim

Jolliffe

Noorani

Rees

Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomised controlled trials. Am J Med 2004; 116:682–692.

14.

Klein

Burke

Bray

Blair

Allison

Pi-Sunyer

Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004; 110:2952–2967.

15.

15 Flack

Neaton

Grimm

Shih

Cutler

Ensrud

MacMahon

. For the Multiple Risk Intervention Trial Research Group. Blood pressure and mortality among men with prior myocardial infarction. Circulation 1995; 92:2437–2445.

16.

16 Law

Wald

Morris

. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 2003; 7:1–94.

17.

17 Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy ant safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267–1278.

18.

Bartnik

Ryden

Ferrari

Malmberg

Pyörälä

Simoons

on behalf of the Euro Heart Survey Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25:1880–1890.

19.

19 Löwel

König

Engel

Hörmann

Keil

. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. Diabetologia 2000; 43:218–226.

20.

Malmberg

Yusuf

Gerstein

Brown

Zhao

Hunt

For the OASIS Registry Investigators. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) registry. Circulation 2000; 102:1014–1019.

21.

McGuire

Emanuelsson

Granger

Ohman

Moliterno

White

Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the Gusto-lib study. Gusto IIb Investigators. Eur Heart J 2000; 21:1750–1758.

22.

22 Mukamal

Nesto

Cohen

Muller

Maclure

Sherwood

Mittleman

. Impact of diabetes on long-term survival after acute myocardial infarction: comparability or risk with prior myocardial infarction. Diabetes Care 2001; 24:1422–1427.

23.

23 Gustafsson

Hildebrandt

Selbaek

Melchior

Torp-Pedersen

Kober

Kaiser-Nielsen

. Long-term prognosis of diabetic patients with myocardial infarction: relation to antidiabetic treatment regimen. The TRACE Study Group. Eur Heart J 2000; 21:1937–1943.

24.

24 Gaede

Vedel

Larsen

Jensen

Parving

Pedersen

. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348:383–393.

25.

25 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk people. BMJ 2002; 324:71–86.

26.

26 Freemantle

Cleland

Young

Mason

Harrison

. β Blockade after myocardial infarction: systematic review and meta regression analysis. B/WJ 1999; 318:1730–1737.

27.

27 Latini

Maggioni

Flather

Sleight

Tognoni

. ACE inhibitor use in people with Myocardial infarction. Summary of evidence from clinical trials. Circulation 1995; 92:3132–3137.

28.

28 Domanski

Exner

Borkowf

Geller

Rosenberg

Pfeffer

. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999; 33:598–604.

29.

29 ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Systematic overview of individual data from 100 000 patients in randomized trials. Circulation 1998; 97:2202–2212.

30.

30 EURORA Investigators. The European Trial on Reduction of Cadiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among people with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782–788.

31.

31 Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Blood pressure lowering treatment trialists' collaboration. Lancet 2003; 362:1527–1535.

32.

32 Anand

Yusuf

. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999; 282:2058–2067.

33.

Bhatt

Steg

Ohman

Hirsch

Ikeda

Mas

For the REACH Registry Investigators. International prevalence, recognition and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295:180–189.

34.

34 Mendis

Abegunde

Yusuf

Ebrahim

Shaper

Ghannem

Shengelia

. (WHO-PREMISE (Phase I) Study Group). Bulletin World Health Organization 2005; 83:820–828.

35.

35 De Velasco

Cosin

Lopez-Sendon

de Teresa

de Oya

Carrasco

Navarro

. La prevencion secundaria del infarto de miocardio en Espana. Estudio PREVESE (Secondary prevention of myocardial infarction in Spain. The PREVESE study). Rev Esp Cardiol 1997; 50:406–415.

36.

36 De Velasco

Cosin

Lopez-Sendon

De Teresa

De Oya

Sellers

. Nuevos datos sobre la prevencion secundaria del infarto de miocardio en Espana. Resultados del estudio PREVESE II. (New data on secondary prevention of myocardial infarction in Spain. Results of the PREVESE II study). Rev Esp Cardiol 2002; 55:801–809.

37.

Danchin

Hanania

Grenier

Vaur

Amelineau

Guéret

pour les investigateurs Usik 1995, Prévenir 1, Prévenir 2 et Usic 2000 et al. Evolution du traitement de sortie apres hospitalisation pour syndrome coronaire aigu en France entre 1995 et 2000: donnees des etudes Usik 1995, Prévenir 1 et 2 et Usic 2000. (Trends in discharge prescriptions for patients hospitalized for acute coronary syndromes in France from 1995 to 2000. Data from the Usik 1995, Prévenir 1, Prévenir 2 and Usic 2000 surveys). Ann Cardiol Angeiol 2003; 52:1–6.

38.

38 Ž

Reiner

Mihatov

Milièić

Bergovec

Planinc

. On behalf of the TASPIC-CRO Study Group Investigators. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study). Eur J Cardiovasc Prev Rehab 2006; 13:646–654.

39.

39 Muntner

DeSalvo

Wildman

Raggi

Whelton

. Trends in the prevalence, awareness, treatment and control of cardiovascular risk factors among noninstitutionalized patients with a history of myocardial infarction and stroke. Am J Epidemiology 2006; 163:913–920.

40.

40 Qureshi

Suri

Guterman

Hopkinset

. Ineffective secondary prevention in survivors of cardiovascular events in the US population: report from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2001; 161:1621–1628.

41.

Khot

Bajzer

Sapp

Ohman

Brener

Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290:898–904.

42.

42 Ghandehary

Kamal-Bahl

Wong

. Prevalence and extent of dyslipidaemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003–2004. Am Heart J 2008; 156:112–119.

43.

43 Fonarow

French

Parsons

Sun

Malmgren

. for the National Registry of myocardial Infarction 3 Participants. Circulation 2001; 103:38–44.

44.

44 Pearson

Laurora

Chu

Kafonek

. Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low density lipoprotein cholesterol goals. Arch Intern Med 2000; 160:459–467.

45.

45 Fox

KAA

Cokkinos

Deckers

Keil

Maggioni

Steg

. On behalf of the ENACT (European Network for Acute Coronary Treatment) Investigators. Eur Heart J 2000; 21:1440–1449.

46.

46 Fox

KAA

Goodman

Klein

Brieger

Steg

Dabbous

Avezum

. For the GRACE Investigators. Management of acute coronary syndromes. Variations in practice and outcome. Eur Heart J 2002; 23:1177–1189.

47.

47 Van Ganse

Laforest

Alemao

Davies

Gutkin

Yin

. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opinion 2005; 21:1389–1399.

48.

48 Heidrich

Behrens

Raspe

Keil

. Knowledge and perception of guidelines and secondary prevention of coronary heart disease among general practitioners and internists. Results from a physician survey in Germany. Eur J Cardiovasc Prev Rehab 2005; 12:521–529.

49.

49 Hobbs

Erhardt

. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Earn Practice 2002; 19:596–604.

50.

Giannuzzi

Saner

Bjornstad

Fioretti

Mendes

Cohen-Solal

Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology. Secondary prevention through cardiac rehabilitation: position paper of the Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology. Eur Heart J 2003; 24:1273–1278.

51.

Wood

Kotseva

Connolly

Jennings

Mead

Jones

EUROACTION Study Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008; 371:1999–2012.